Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone


  • Arcani Robin
  • Venton Geoffroy
  • Colle Julien
  • Suchon Pierre
  • Ivanov Vadim
  • Mercier Cédric
  • Farnault Laure
  • Roche Pauline
  • Lafage Marina
  • Brunet Corinne
  • Azouza Wakil
  • Pourroy Bertrand
  • Fanciullino Raphaelle
  • Costello Régis


  • Bortezomib
  • Immunomodulatory therapy
  • Lenalidomide
  • Multiple myeloma

document type



Recently, phase III trials assessed a new combination of lenalidomide, bortezomib, and dexamethasone (RVD) in induction therapy in transplantation‐eligible multiple myeloma (MM) patients, before consolidation with RVD and lenalidomide maintenance. We present a retrospective study evaluating this approach with patients from the real life.

more information